Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
(1) Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker st...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-09, Vol.14 (19), p.4757 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 19 |
| container_start_page | 4757 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Jiménez, Natalia Reig, Òscar Marín-Aguilera, Mercedes Aversa, Caterina Ferrer-Mileo, Laura Font, Albert Rodriguez-Vida, Alejo Climent, Miguel Ángel Cros, Sara Chirivella, Isabel Domenech, Montserrat Figols, Mariona González-Billalabeitia, Enrique Jiménez Peralta, Daniel Rodríguez-Carunchio, Leonardo García-Esteve, Samuel Garcia de Herreros, Marta Ribal, Maria J Prat, Aleix Mellado, Begoña |
| description | (1) Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3–0.9; p = 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4–0.9; p = 0.019) and OS (HR 0.5, 95% CI 0.2–0.9, p = 0.024), and lower expression of tumor suppressor genes (TSG) (RB1, PTEN and TP53) with shorter OS (HR 2, 95% CI 1–3.8; p = 0.044). ARV7 expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1–2.1, p = 0.008) and OS (HR 1.8, 95% CI 1.2–2.6, p = 0.004), high ESR2 was associated with longer OS (HR 0.5, 95% CI 0.2–1, p = 0.048) and low expression of RB1 was independently associated with shorter OS (HR 1.9, 95% CI 1.1–3.2, p = 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as ARV7, RB1, and ESR2 expression, have a prognostic value in mHSPC patients treated with ADT+DX. |
| doi_str_mv | 10.3390/cancers14194757 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9564355</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A745271825</galeid><sourcerecordid>A745271825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-cc0379b8ebf2a2ea87343de7638de9084b6520bd5d22dc655be783c3ea5a11853</originalsourceid><addsrcrecordid>eNptkkFvFSEQxzdGY5vas1cSL162XWCB3YvJy6tak5qa-DwTFmZfaVh4Avu0H6XfVrZtrG2EAyTzn99_YKaq3uLmhNK-OdXKa4gJt7hvBRMvqkPSCFJz3rcv_7kfVMcpXTdlUYoFF6-rA8oJbXiHD6vbTVQ-6Wh32QavHPoWw2gdoFVKQVuVwaBfNl-htbPe6iK4nLMOEyRkPfoKWaWsstXoPMQpeKi_g0822z0spCUGaH1XJ9pEeMStvIlhCx6dwS7avVrckfIGnQVdoL_BvalejcolOH44j6ofnz5u1uf1xeXnL-vVRa1bznKtdUNFP3QwjEQRUJ2gLTUgOO0M9E3XDpyRZjDMEGI0Z2wA0VFNQTGFccfoUfXhnrubhwmMBp-jcrJUNal4I4Oy8mnE2yu5DXvZM95StgDePwBi-DlDynKySYNzykOYkySCMNwLQvsiffdMeh3mWL79TtUS0pVaH1Vb5UBaP4biqxeoXImWEYE7stie_EdVtoHJ6tKKpY1PE07vE3RpTIow_n0jbuQyUPLZQNE_U1jAkw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2724228520</pqid></control><display><type>article</type><title>Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Jiménez, Natalia ; Reig, Òscar ; Marín-Aguilera, Mercedes ; Aversa, Caterina ; Ferrer-Mileo, Laura ; Font, Albert ; Rodriguez-Vida, Alejo ; Climent, Miguel Ángel ; Cros, Sara ; Chirivella, Isabel ; Domenech, Montserrat ; Figols, Mariona ; González-Billalabeitia, Enrique ; Jiménez Peralta, Daniel ; Rodríguez-Carunchio, Leonardo ; García-Esteve, Samuel ; Garcia de Herreros, Marta ; Ribal, Maria J ; Prat, Aleix ; Mellado, Begoña</creator><creatorcontrib>Jiménez, Natalia ; Reig, Òscar ; Marín-Aguilera, Mercedes ; Aversa, Caterina ; Ferrer-Mileo, Laura ; Font, Albert ; Rodriguez-Vida, Alejo ; Climent, Miguel Ángel ; Cros, Sara ; Chirivella, Isabel ; Domenech, Montserrat ; Figols, Mariona ; González-Billalabeitia, Enrique ; Jiménez Peralta, Daniel ; Rodríguez-Carunchio, Leonardo ; García-Esteve, Samuel ; Garcia de Herreros, Marta ; Ribal, Maria J ; Prat, Aleix ; Mellado, Begoña</creatorcontrib><description>(1) Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3–0.9; p = 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4–0.9; p = 0.019) and OS (HR 0.5, 95% CI 0.2–0.9, p = 0.024), and lower expression of tumor suppressor genes (TSG) (RB1, PTEN and TP53) with shorter OS (HR 2, 95% CI 1–3.8; p = 0.044). ARV7 expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1–2.1, p = 0.008) and OS (HR 1.8, 95% CI 1.2–2.6, p = 0.004), high ESR2 was associated with longer OS (HR 0.5, 95% CI 0.2–1, p = 0.048) and low expression of RB1 was independently associated with shorter OS (HR 1.9, 95% CI 1.1–3.2, p = 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as ARV7, RB1, and ESR2 expression, have a prognostic value in mHSPC patients treated with ADT+DX.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14194757</identifier><identifier>PMID: 36230681</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Androgen receptors ; Androgens ; Biomarkers ; Biopsy ; Cancer therapies ; Care and treatment ; Castration ; Clinical outcomes ; Cluster analysis ; Docetaxel ; Dosage and administration ; Estrogen receptors ; Gene expression ; Genetic aspects ; Genetic transcription ; Health aspects ; Metastases ; Metastasis ; p53 Protein ; Patient outcomes ; Patients ; Prostate cancer ; PTEN protein ; Retinoblastoma protein ; Software ; Survival ; Transcriptomics ; Tumor suppressor genes ; Tumors ; Variables</subject><ispartof>Cancers, 2022-09, Vol.14 (19), p.4757</ispartof><rights>COPYRIGHT 2022 MDPI AG</rights><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-cc0379b8ebf2a2ea87343de7638de9084b6520bd5d22dc655be783c3ea5a11853</citedby><cites>FETCH-LOGICAL-c465t-cc0379b8ebf2a2ea87343de7638de9084b6520bd5d22dc655be783c3ea5a11853</cites><orcidid>0000-0002-7680-2048 ; 0000-0001-7563-3812 ; 0000-0002-7057-0426 ; 0000-0002-0733-3276 ; 0000-0002-2933-3357 ; 0000-0002-8088-5966 ; 0000-0003-2377-540X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564355/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564355/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Jiménez, Natalia</creatorcontrib><creatorcontrib>Reig, Òscar</creatorcontrib><creatorcontrib>Marín-Aguilera, Mercedes</creatorcontrib><creatorcontrib>Aversa, Caterina</creatorcontrib><creatorcontrib>Ferrer-Mileo, Laura</creatorcontrib><creatorcontrib>Font, Albert</creatorcontrib><creatorcontrib>Rodriguez-Vida, Alejo</creatorcontrib><creatorcontrib>Climent, Miguel Ángel</creatorcontrib><creatorcontrib>Cros, Sara</creatorcontrib><creatorcontrib>Chirivella, Isabel</creatorcontrib><creatorcontrib>Domenech, Montserrat</creatorcontrib><creatorcontrib>Figols, Mariona</creatorcontrib><creatorcontrib>González-Billalabeitia, Enrique</creatorcontrib><creatorcontrib>Jiménez Peralta, Daniel</creatorcontrib><creatorcontrib>Rodríguez-Carunchio, Leonardo</creatorcontrib><creatorcontrib>García-Esteve, Samuel</creatorcontrib><creatorcontrib>Garcia de Herreros, Marta</creatorcontrib><creatorcontrib>Ribal, Maria J</creatorcontrib><creatorcontrib>Prat, Aleix</creatorcontrib><creatorcontrib>Mellado, Begoña</creatorcontrib><title>Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel</title><title>Cancers</title><description>(1) Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3–0.9; p = 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4–0.9; p = 0.019) and OS (HR 0.5, 95% CI 0.2–0.9, p = 0.024), and lower expression of tumor suppressor genes (TSG) (RB1, PTEN and TP53) with shorter OS (HR 2, 95% CI 1–3.8; p = 0.044). ARV7 expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1–2.1, p = 0.008) and OS (HR 1.8, 95% CI 1.2–2.6, p = 0.004), high ESR2 was associated with longer OS (HR 0.5, 95% CI 0.2–1, p = 0.048) and low expression of RB1 was independently associated with shorter OS (HR 1.9, 95% CI 1.1–3.2, p = 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as ARV7, RB1, and ESR2 expression, have a prognostic value in mHSPC patients treated with ADT+DX.</description><subject>Androgen receptors</subject><subject>Androgens</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Castration</subject><subject>Clinical outcomes</subject><subject>Cluster analysis</subject><subject>Docetaxel</subject><subject>Dosage and administration</subject><subject>Estrogen receptors</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Genetic transcription</subject><subject>Health aspects</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>p53 Protein</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>PTEN protein</subject><subject>Retinoblastoma protein</subject><subject>Software</subject><subject>Survival</subject><subject>Transcriptomics</subject><subject>Tumor suppressor genes</subject><subject>Tumors</subject><subject>Variables</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkkFvFSEQxzdGY5vas1cSL162XWCB3YvJy6tak5qa-DwTFmZfaVh4Avu0H6XfVrZtrG2EAyTzn99_YKaq3uLmhNK-OdXKa4gJt7hvBRMvqkPSCFJz3rcv_7kfVMcpXTdlUYoFF6-rA8oJbXiHD6vbTVQ-6Wh32QavHPoWw2gdoFVKQVuVwaBfNl-htbPe6iK4nLMOEyRkPfoKWaWsstXoPMQpeKi_g0822z0spCUGaH1XJ9pEeMStvIlhCx6dwS7avVrckfIGnQVdoL_BvalejcolOH44j6ofnz5u1uf1xeXnL-vVRa1bznKtdUNFP3QwjEQRUJ2gLTUgOO0M9E3XDpyRZjDMEGI0Z2wA0VFNQTGFccfoUfXhnrubhwmMBp-jcrJUNal4I4Oy8mnE2yu5DXvZM95StgDePwBi-DlDynKySYNzykOYkySCMNwLQvsiffdMeh3mWL79TtUS0pVaH1Vb5UBaP4biqxeoXImWEYE7stie_EdVtoHJ6tKKpY1PE07vE3RpTIow_n0jbuQyUPLZQNE_U1jAkw</recordid><startdate>20220929</startdate><enddate>20220929</enddate><creator>Jiménez, Natalia</creator><creator>Reig, Òscar</creator><creator>Marín-Aguilera, Mercedes</creator><creator>Aversa, Caterina</creator><creator>Ferrer-Mileo, Laura</creator><creator>Font, Albert</creator><creator>Rodriguez-Vida, Alejo</creator><creator>Climent, Miguel Ángel</creator><creator>Cros, Sara</creator><creator>Chirivella, Isabel</creator><creator>Domenech, Montserrat</creator><creator>Figols, Mariona</creator><creator>González-Billalabeitia, Enrique</creator><creator>Jiménez Peralta, Daniel</creator><creator>Rodríguez-Carunchio, Leonardo</creator><creator>García-Esteve, Samuel</creator><creator>Garcia de Herreros, Marta</creator><creator>Ribal, Maria J</creator><creator>Prat, Aleix</creator><creator>Mellado, Begoña</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7680-2048</orcidid><orcidid>https://orcid.org/0000-0001-7563-3812</orcidid><orcidid>https://orcid.org/0000-0002-7057-0426</orcidid><orcidid>https://orcid.org/0000-0002-0733-3276</orcidid><orcidid>https://orcid.org/0000-0002-2933-3357</orcidid><orcidid>https://orcid.org/0000-0002-8088-5966</orcidid><orcidid>https://orcid.org/0000-0003-2377-540X</orcidid></search><sort><creationdate>20220929</creationdate><title>Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel</title><author>Jiménez, Natalia ; Reig, Òscar ; Marín-Aguilera, Mercedes ; Aversa, Caterina ; Ferrer-Mileo, Laura ; Font, Albert ; Rodriguez-Vida, Alejo ; Climent, Miguel Ángel ; Cros, Sara ; Chirivella, Isabel ; Domenech, Montserrat ; Figols, Mariona ; González-Billalabeitia, Enrique ; Jiménez Peralta, Daniel ; Rodríguez-Carunchio, Leonardo ; García-Esteve, Samuel ; Garcia de Herreros, Marta ; Ribal, Maria J ; Prat, Aleix ; Mellado, Begoña</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-cc0379b8ebf2a2ea87343de7638de9084b6520bd5d22dc655be783c3ea5a11853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Androgen receptors</topic><topic>Androgens</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Castration</topic><topic>Clinical outcomes</topic><topic>Cluster analysis</topic><topic>Docetaxel</topic><topic>Dosage and administration</topic><topic>Estrogen receptors</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Genetic transcription</topic><topic>Health aspects</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>p53 Protein</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>PTEN protein</topic><topic>Retinoblastoma protein</topic><topic>Software</topic><topic>Survival</topic><topic>Transcriptomics</topic><topic>Tumor suppressor genes</topic><topic>Tumors</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiménez, Natalia</creatorcontrib><creatorcontrib>Reig, Òscar</creatorcontrib><creatorcontrib>Marín-Aguilera, Mercedes</creatorcontrib><creatorcontrib>Aversa, Caterina</creatorcontrib><creatorcontrib>Ferrer-Mileo, Laura</creatorcontrib><creatorcontrib>Font, Albert</creatorcontrib><creatorcontrib>Rodriguez-Vida, Alejo</creatorcontrib><creatorcontrib>Climent, Miguel Ángel</creatorcontrib><creatorcontrib>Cros, Sara</creatorcontrib><creatorcontrib>Chirivella, Isabel</creatorcontrib><creatorcontrib>Domenech, Montserrat</creatorcontrib><creatorcontrib>Figols, Mariona</creatorcontrib><creatorcontrib>González-Billalabeitia, Enrique</creatorcontrib><creatorcontrib>Jiménez Peralta, Daniel</creatorcontrib><creatorcontrib>Rodríguez-Carunchio, Leonardo</creatorcontrib><creatorcontrib>García-Esteve, Samuel</creatorcontrib><creatorcontrib>Garcia de Herreros, Marta</creatorcontrib><creatorcontrib>Ribal, Maria J</creatorcontrib><creatorcontrib>Prat, Aleix</creatorcontrib><creatorcontrib>Mellado, Begoña</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>Proquest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiménez, Natalia</au><au>Reig, Òscar</au><au>Marín-Aguilera, Mercedes</au><au>Aversa, Caterina</au><au>Ferrer-Mileo, Laura</au><au>Font, Albert</au><au>Rodriguez-Vida, Alejo</au><au>Climent, Miguel Ángel</au><au>Cros, Sara</au><au>Chirivella, Isabel</au><au>Domenech, Montserrat</au><au>Figols, Mariona</au><au>González-Billalabeitia, Enrique</au><au>Jiménez Peralta, Daniel</au><au>Rodríguez-Carunchio, Leonardo</au><au>García-Esteve, Samuel</au><au>Garcia de Herreros, Marta</au><au>Ribal, Maria J</au><au>Prat, Aleix</au><au>Mellado, Begoña</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel</atitle><jtitle>Cancers</jtitle><date>2022-09-29</date><risdate>2022</risdate><volume>14</volume><issue>19</issue><spage>4757</spage><pages>4757-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>(1) Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3–0.9; p = 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4–0.9; p = 0.019) and OS (HR 0.5, 95% CI 0.2–0.9, p = 0.024), and lower expression of tumor suppressor genes (TSG) (RB1, PTEN and TP53) with shorter OS (HR 2, 95% CI 1–3.8; p = 0.044). ARV7 expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1–2.1, p = 0.008) and OS (HR 1.8, 95% CI 1.2–2.6, p = 0.004), high ESR2 was associated with longer OS (HR 0.5, 95% CI 0.2–1, p = 0.048) and low expression of RB1 was independently associated with shorter OS (HR 1.9, 95% CI 1.1–3.2, p = 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as ARV7, RB1, and ESR2 expression, have a prognostic value in mHSPC patients treated with ADT+DX.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>36230681</pmid><doi>10.3390/cancers14194757</doi><orcidid>https://orcid.org/0000-0002-7680-2048</orcidid><orcidid>https://orcid.org/0000-0001-7563-3812</orcidid><orcidid>https://orcid.org/0000-0002-7057-0426</orcidid><orcidid>https://orcid.org/0000-0002-0733-3276</orcidid><orcidid>https://orcid.org/0000-0002-2933-3357</orcidid><orcidid>https://orcid.org/0000-0002-8088-5966</orcidid><orcidid>https://orcid.org/0000-0003-2377-540X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-09, Vol.14 (19), p.4757 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9564355 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Androgen receptors Androgens Biomarkers Biopsy Cancer therapies Care and treatment Castration Clinical outcomes Cluster analysis Docetaxel Dosage and administration Estrogen receptors Gene expression Genetic aspects Genetic transcription Health aspects Metastases Metastasis p53 Protein Patient outcomes Patients Prostate cancer PTEN protein Retinoblastoma protein Software Survival Transcriptomics Tumor suppressor genes Tumors Variables |
| title | Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A08%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transcriptional%20Profile%20Associated%20with%20Clinical%20Outcomes%20in%20Metastatic%20Hormone-Sensitive%20Prostate%20Cancer%20Treated%20with%20Androgen%20Deprivation%20and%20Docetaxel&rft.jtitle=Cancers&rft.au=Jim%C3%A9nez,%20Natalia&rft.date=2022-09-29&rft.volume=14&rft.issue=19&rft.spage=4757&rft.pages=4757-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14194757&rft_dat=%3Cgale_pubme%3EA745271825%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2724228520&rft_id=info:pmid/36230681&rft_galeid=A745271825&rfr_iscdi=true |